Tibaldi J, et al. - In routine clinical practice in the United States, researchers compared the real-world effectiveness of insulin degludec (degludec) vs glargine 300 units/mL (glargine U300) in insulin-naïve adults with type 2 diabetes. The primary endpoint—HbA1c change from baseline to 180 days of follow-up—was evaluated via repeated-measure of covariance analysis with subjects as a random effect. Using negative binomial and logistic regression, change in the rate of hypoglycemic episodes and change in proportion of patients with hypoglycemia were estimated. Data for 4,056 patients were analyzed. Degludec treatment resulted in significantly greater reductions of HbA1c, with a 30% lower risk of hypoglycemia and a reduced likelihood of discontinuation of treatment vs glargine U300 treatment.